Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease.

Yuan-Lung Cheng,Han-Chieh Lin,Shou-Dong Lee,Yi-Hsiang Huang,Yuan-Jen Wang,Keng-Hsin Lan,Jaw-Ching Wu,Wei-Yao Hsieh,Chien-Wei Su,Teh-Ia Huo,Fa-Yauh Lee,Ming-Chih Hou

doi:10.1155/2017/9279836

Abstract

Background. Fatty liver index (FLI) and lipid accumulation product (LAP) are indexes originally designed to assess the risk of fatty liver and cardiovascular disease, respectively. Both indexes have been proven to be reliable markers of subsequent metabolic syndrome; however, their ability to predict metabolic syndrome in subjects without fatty liver disease has not been clarified. Methods. We enrolled consecutive subjects who received health check-up services at Taipei Veterans General Hospital from 2002 to 2009. Fatty liver disease was diagnosed by abdominal ultrasonography. The ability of the FLI and LAP to predict metabolic syndrome was assessed by analyzing the area under the receiver operating characteristic (AUROC) curve. Results. Male sex was strongly associated with metabolic syndrome, and the LAP and FLI were better than other variables to predict metabolic syndrome among the 29,797 subjects. Both indexes were also better than other variables to detect metabolic syndrome in subjects without fatty liver disease (AUROC: 0.871 and 0.879, resp.), and the predictive power was greater among women. Conclusion. Metabolic syndrome increases the cardiovascular disease risk. The FLI and LAP could be used to recognize the syndrome in both subjects with and without fatty liver disease who require lifestyle modifications and counseling.

Highlights

Metabolic syndrome comprises risk factors of cardiovascular disease and type 2 diabetes mellitus (DM), including central obesity, dyslipidemia, and high blood pressure and fasting glucose [1]
Subjects with metabolic syndrome tended to be older in age, be male, have a higher body mass index (BMI), serum total cholesterol, low-density lipoprotein cholesterol (LDL-c), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and fatty liver prevalence, and have lower platelet counts
The Fatty liver index (FLI) and lipid accumulation product (LAP) are indexes originally designed to assess the risk of fatty liver and cardiovascular disease, respectively, and both have been shown to be good markers of metabolic syndrome [4, 10, 12, 13]

Summary

Introduction

Metabolic syndrome comprises risk factors of cardiovascular disease and type 2 diabetes mellitus (DM), including central obesity, dyslipidemia, and high blood pressure and fasting glucose [1]. Fatty liver index (FLI) and lipid accumulation product (LAP) are indexes originally designed to assess the risk of fatty liver and cardiovascular disease, respectively. Both indexes have been proven to be reliable markers of subsequent metabolic syndrome; their ability to predict metabolic syndrome in subjects without fatty liver disease has not been clarified. Male sex was strongly associated with metabolic syndrome, and the LAP and FLI were better than other variables to predict metabolic syndrome among the 29,797 subjects Both indexes were better than other variables to detect metabolic syndrome in subjects without fatty liver disease (AUROC: 0.871 and 0.879, resp.), and the predictive power was greater among women. The FLI and LAP could be used to recognize the syndrome in both subjects with and without fatty liver disease who require lifestyle modifications and counseling

Methods

Results

Conclusion